NasdaqGS:PCRXPharmaceuticals
Is Pacira BioSciences' (PCRX) Balance of Buybacks and New Equity Signaling a Strategic Shift?
Pacira BioSciences recently reported a second quarter net loss of US$4.85 million despite slightly higher revenue year-over-year and narrowed its full-year 2025 revenue guidance to US$730 million–US$750 million.
Alongside these financial results, the company completed a share buyback program and filed a US$57.35 million shelf registration, indicating a focus on both capital allocation and potential new equity offerings.
We'll examine how the combination of widened losses and lowered revenue...